Portal de Periódicos da CAPES

Mucocutaneous Reactions to Antineoplastic Agents

1980; Wiley; Volume: 30; Issue: 3 Linguagem: Inglês

10.3322/canjclin.30.3.143

1542-4863

R. M. Adrian, Antoinette F. Hood, Arthur T. Skarin,

Chronic Lymphocytic Leukemia Research

CA: A Cancer Journal for CliniciansVolume 30, Issue 3 p. 143-157 FeatureFree Access Mucocutaneous reactions to antineoplastic agents Robert M. Adrian M.D., Robert M. Adrian M.D. Fellow in Dermatology and Instructor, Massachusetts General Hospital, Harvard Medical School, Boston, MassachusettsSearch for more papers by this authorAntoinette F. Hood M.D., Antoinette F. Hood M.D. Fellow in Dermatology and Instructor, Massachusetts General Hospital, Harvard Medical School, Boston, MassachusettsSearch for more papers by this authorArthur T. Skarin M.D., Arthur T. Skarin M.D. Associate Professor of Medicine, Medical Oncology Division, Sidney Farber Cancer Institute; and Associate Professor of Medicine, Harvard Medical School, Boston, MassachusettsSearch for more papers by this author Robert M. Adrian M.D., Robert M. Adrian M.D. Fellow in Dermatology and Instructor, Massachusetts General Hospital, Harvard Medical School, Boston, MassachusettsSearch for more papers by this authorAntoinette F. Hood M.D., Antoinette F. Hood M.D. Fellow in Dermatology and Instructor, Massachusetts General Hospital, Harvard Medical School, Boston, MassachusettsSearch for more papers by this authorArthur T. Skarin M.D., Arthur T. Skarin M.D. Associate Professor of Medicine, Medical Oncology Division, Sidney Farber Cancer Institute; and Associate Professor of Medicine, Harvard Medical School, Boston, MassachusettsSearch for more papers by this author First published: May/June 1980 https://doi.org/10.3322/canjclin.30.3.143Citations: 12AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Reference 1 Chabner BA, Myers CE, Coleman CN, et al: The clinical pharmacology of antineoplastic agents. N Engl J Med 292: 1107– 1113, 1159-1168, 1975. 2 DeVita VT, Schein PS: The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med 288: 998– 1006, 1973. 3 Chabner B, Myers CE, Oliverio VT: Clinical pharmacology of anti-cancer drugs. Semin Oncol 4: 165– 191, 1977. 4 Levantine A, Almeyda J: Drug reactions. XXIV. Cutaneous reactions to cytostatic agents. Br J Dermatol 90: 239– 242, 1974. 5 Dreizen S, Bodey GP, Rodriquez V, et al: Cutaneous complications of cancer chemotherapy. Postgrad Med 58: 150– 158, 1975. 6 Moschella SL, Pillsbury DM, Hurley HJ: Dermatology. Philadelphia, WB Saunders Co, 1975, pp 1191– 1221. 7 Crounse RG, Van Scott EJ: Changes in scalp hair roots as a measure of toxicity from cancer chemotherapeutic drugs. J Invest Dermatol 35: 83– 90, 1960. 8 Soukop M, Campbell A, Gray MM, et al: Adriamycin, alopecia, and the scalp tourniquet. Cancer Treat Rep 62: 489– 490, 1978. 9 Edelstyn GA, MacRae KD, MacDonald FM: Improvement of life quality in cancer patients undergoing chemotherapy. Clin Oncol 5: 43– 49, 1979. 10 Dreizen S. Bodey GP, odriquez V: Oral complications of cancer chemotherapy. Postgrad Med 58: 75– 82, 1975. 11 Phillips TL, Fu KK: Acute and late effects of multi-modal therapy on normal tissues. Cancer 40: 489– 494, 1977. 12 Phillips TL, Fu KK: Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer 37: 1186– 1200, 1976. 13 Cohen SC, DiBella NJ, Michalak JC: Recall injury from adriamycin. Ann Intern Med 83: 232, 1975. 14 Greco FA, Brereton HD, Kent H, et al: Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 85: 294– 298, 1976. 15 Malacrane P, Zavagli G: Melphalan-induced melanonychia striata. Arch Dermatol Res 258: 81– 83, 1977. 16 Kyle RA, Schwartz RS, Oliner HL, et al: A syndrome resembling adrenal cortical insufficiency associated with long term busulfan (Myleran) therapy. Blood 18: 497– 510, 1961. 17 Burns WA, McFarland W, Matthews MJ: Toxic manifestations of busulfan therapy. Med Ann DC 40: 567– 572, 1971. 18 Galton DA: Myleran in chronic myeloid leukaemia; results of treatment. Lancet 1: 208– 213, 1953. 19 Dahlgren S, Holm G, Svanborg N, et al: Clinical and morphological side-effects of busulfan (Myleran) treatment. Acta Med Scand 192: 129– 135, 1972. 20 Kyle RA, Dameshek W: Porphyria cutanea tarda associated with chronic granulocytic leukemia treated with busulfan. Blood 23: 776– 783, 1964. 21 Dosik H, Hurewitz DJ, Rosner F, et al: Bullous eruption and elevated leukocyte alkaline phosphatase in the course of busulfan-treated chronic granulocytic leukemia. Blood 35: 543– 548, 1970. 22 Flaxman BA, Sosis AC, Van Scott EJ: Changes in melanosome distribution in Caucasoid skin following topical application of nitrogen mustard. J Invest Dermatol 60: 321– 326, 1973. 23 Toda K, Pathak MA, Parrish JA, et al: Alteration of racial differences in melanosome distribution in human epidermis after exposure to ultraviolet light. Nature 236: 143– 145, 1972. 24 Ross WE, Chabner BA: Allergic reaction to cyclophosphamide in a melchlorethamine-sensitive patient. Cancer Treat Rep 61: 495– 496, 1977. 25 Shah PC, Rao KR, Patel AR: Cyclophosphamide induced nail pigmentation. Br J Dermatol 98: 675– 680, 1978. 26 Harrison BM, Wood CBS: Cyclophosphamide and pigmentation. Br Med J 2: 352, 1972. 27 Solidoro A, Saenz R: Effects of cyclophosphamide (NSC-26271) on 127 patients with malignant lymphoma. Cancer Chemother Rep 50: 265– 270, 1966. 28 Moller H: Reactivation of acute inflammation by methotrexate. J Invest Dermatol 52: 437– 441, 1969. 29 Möller H: Methotrexate and the ultraviolet light inflammation in the guinea pig. Dermatologica 140: 225– 230, 1970. 30 Corder MP, Stone WH: Failure of leucovorin rescue to prevent reactivation of a solar burn after high dose methotrexate. Cancer 37: 1660– 1662, 1976. 31 Weinstein GD: Methotrexate. Ann Intern Med 86: 199– 204, 1977. 32 Berlin NI, Rail D, Mead J A, et al: Folic acid antagonist. Effects on the cell and the patient. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 59: 931– 956, 1963. 33 Falkson G, Schulz EJ: Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 74: 229– 236, 1962. 34 Hrushesky WJ: Serpentine supra venous 5-fluorouracil hyperpigmentation. JAMA 236: 138, 1976. 35 Bernstein T: Skin reactions to 5-fluorouracil. N Engl J Med 297: 337– 338, 1977. 36 Omura EF, Torre D: Inflammation of actinic keratoses due to systemic fluorouracil therapy. JAMA 208: 150– 151, 1969. 37 Epstein EH, Lutzner MA: Folliculitis induced by actinomycin-D. N Engl J Med 281: 1094– 1096, 1969. 38 Rudolph R, Stein RS, Pattillo RA: Skin ulcers due to adriamycin. Cancer 38: 1087– 1094, 1976. 39 Reilly JJ, Neifeld JP, Rosenberg SA: Clinical course and management of accidental adriamycin extravasation. Cancer 40: 2053– 2056, 1977. 40 Souhami L Jr, Feld R: Urticaria following intravenous doxorubicin administration. JAMA 240: 1624– 1626, 1978. 41 Etcubanas E, Wilbur JR: Uncommon side effects of adriamycin. Cancer Chemother Rep 58: 757– 758, 1974. 42 Manalo FB, Marks A, Davis HL Jr: Doxorubicin toxicity. Oncholysis, plantar callus formation, and epidermolysis. JAMA 233: 56– 57, 1975. 43 Morris D, Aisner J, Wiernik PH: Horizontal pigmented banding of the nails in association with adriamycin chemotherapy. Cancer Treat Rep 61: 499– 501, 1977. 44 Priestman TJ, James KW: Adriamycin and longitudinal pigmented banding of fingernails. Lancet 1: 1337– 1338, 1975. 45 Kew MC, Mzamane D, Smith AG, et al: Melanocyte-stimulating-hormone levels in doxorubicin-induced hyperpigmentation. Lancet 1: 811, 1977. 46 Rao SP, Potnis AV, Sobrinho TC, et al: Pigmentation of the tongue after treatment with adriamycin. Cancer Treat Rep 60: 1402– 1404, 1976. 47 deMarinis M, Hendricks A, Stotzner G: Nail pigmentation with daunorubicin therapy. Ann Intern Med 89: 516– 517, 1978. 48 Bennett JM, Reich SD: Bleomycin. Ann Intern Med 90: 945– 948, 1979. 49 Werner Y, Törnberg B: Cutaneous side effects of bleomycin therapy. Acta Derm Venereol 56: 155– 158, 1976. 50 Cohen IS, Mosher MB, O'Keefe EG, et al: Cutaneous toxicity of bleomycin therapy. Arch Dermatol 107: 553– 555, 1973. 51 Shetty MR: Case of pigmented banding of the nail caused by bleomycin. Cancer Treat Rep 61: 501– 502, 1977. 52 Teutch C, Lipton A, Harvey HA: Raynauďs phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep 61: 925– 926, 1977. 53 Sable AR: Chronic bleomycin-associated Raynauďs phenomenon. Cancer Treat Rep 62: 570, 1978. 54 Chernicoff DP, Bukowski RM, Young JR: Raynauďs phenomenon after bleomycin treatement. Cancer Treat Rep 62: 570– 571, 1978. 55 Ihde DC, Gormley PE, Francis RS, et al: Reversible penile calcifications associated with bleomycin-induced pulmonary toxicity. Cancer Chemother Rep 59: 1039– 1041, 1975. 56 Kennedy BJ: Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med 49: 494– 503, 1970. 57 Eyster FE, Wilson CB, Maibach HI: Mithramycin as a possible cause of toxic epidermal necrolysis (Lyelľs syndrome). Calif Med 114: 42– 43, 1971. 58 Purpora D, Ahern MJ, Silverman N: Toxic epidermal necrolysis after mithramycin. N Engl J Med 299: 1412, 1978. 59 Breza TS, Helprin KM, Taylor JR: Photosensitivity reaction to vinblastine. Arch Dermatol 111: 1168– 1170. 1975. 60 Grekin DA, Zackheim HS, Epstein EH: Topical chemotherapy of mycosis fungoides. Cutis 24: 543– 546, 1979. 61 Killander D, Dohlwitz A, Engstedt L, et al: Hypersensitivity reactions and antibody formation during L-Asparaginase treatment of children and adults with acute leukemia. Cancer 37: 220– 228, 1976. 62 Rosten M: Hydroxyurea:a new antimetabolite in the treatment of psoriasis. Br J Dermatol 85: 177– 181, 1971. 63 Kennedy BJ, Smith LR, Goltz RW: Skin changes secondary to hydroxyurea therapy. Arch Dermatol 111: 183– 187, 1975. 64 Brulé G, Schlumberger JR, Griscelli C: N-isopropyl-α (2-methylhydralazino)-p-to-luamide, hydrochloride (NSC-77213) in treatment of solid tumors. Cancer Chemother Rep 44: 31– 38, 1965. 65 Mathé G, Schweisguth O, Schneider M, et al: Methyl-hydrazine in treatment of Hodgkin's disease and various forms of haematosarcoma and leukaemia. Lancet 2: 1077– 1080, 1963. 66 Rozencweig M, von Hoff DD, Slavik M, et al: Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med 86: 803– 812, 1977. 67 Legha SS, Slavik M, Carter SK: Hexamethylmelamine. Cancer 38: 27– 34. 1976. Citing Literature Volume30, Issue3May/June 1980Pages 143-157 ReferencesRelatedInformation